Alpha‐blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta‐analysis. A report from the Neuro‐Urology Promotion Committee of the International Continence Society (ICS)
- 16 May 2019
- journal article
- review article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (6) , 1482-1491
Abstract
Aim: We aimed to systematically assess the evidence on the efficacy and safety of alpha‐blockers in patients with multiple sclerosis (MS) suffering from neurogenic lower urinary tract dysfunction (NLUTD).Methods: The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement was used to perform this systematic review. An electronic search of Cochrane register, Embase, Medline, Scopus (last search 3 March 2018) and screening of reference lists as well as reviews were used to identify the studies. Articles were included if they reported on efficacy/safety of alpha‐blockers for the treatment of NLUTD in patients with MS.Results: After screening of 7′015 abstracts, three studies enrolling a total of 50 patients were included: one randomized, placebo‐controlled, single‐blind trial and two prospective cohort studies. Alpha‐blocker treatment was successful in 50% to 96% of the patients. Pooling data from the three included studies, the relative risk for successful alpha‐blocker treatment was 3.89 (95% confidence interval 2.7‐7.0). The general safety profile of alpha‐blockers was favorable with 8% of the patients reporting adverse events.Conclusions: Alpha‐blockers may be effective and safe for treating NLUTD in female and male patients with MS but the studies were small and the overall quality of evidence was low. To make definitive conclusions, well designed randomized controlled trials are highly warranted.Keywords
Funding Information
- Schweizerische Akademie der Medizinischen Wissenschaften
- Swiss Continence Foundation
This publication has 18 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- INCREASED CONTRACTILE RESPONSE TO PHENYLEPHRINE IN DETRUSOR OF PATIENTS WITH BLADDER OUTLET OBSTRUCTION: EFFECT OF THE α1A AND α1D-ADRENERGIC RECEPTOR ANTAGONIST TAMSULOSINJournal of Urology, 2005
- Tamsulosin: Efficacy and Safety in Patients With Neurogenic Lower Urinary Tract Dysfunction Due to Suprasacral Spinal Cord InjuryJournal of Urology, 2003
- Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury researchBMJ, 2000
- EVIDENCE FOR PREDOMINANT MEDIATION OF α 1 -ADRENOCEPTOR IN THE TONUS OF ENTIRE URETHRA OF WOMENJournal of Urology, 1999
- Sympathetic efferent pathways projecting to the bladder neck and proximal urethra in the ratJournal of the Autonomic Nervous System, 1997
- Do Alpha-Blockers Have a Role in Lower Urinary Tract Dysfunction in Multiple Sclerosis?Journal of Urology, 1995
- Inhibition of Central Sympathetic and Somatic Outflow to the Lower Urinary Tract of the Cat by the Alpha sub 1 Adrenergic Receptor Antagonist PrazosinJournal of Urology, 1995
- Exploratory or analytic meta-analysis: Should we distinguish between them?Journal of Clinical Epidemiology, 1995
- Alpha-Blockers and Urethral Pressure in Neurological PatientsUrologia Internationalis, 1978